Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy

Endocrine

Volumn 50, Issue 2, 2015, Pages 344-354

  Lassemillante, Annie Claude M ^a   Doi, Suhail A R ^a   Hooper, John D ^a   Prins, John B ^a   Wright, Olivia R L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Androgen deprivation therapy; Bone health; Meta analysis; Osteopenia; Osteoporosis; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE MASS; CANCER SURVIVOR; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; CHEMICALLY INDUCED; COMPLICATION; META ANALYSIS; MIDDLE AGED; PROSTATIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 84945465881     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0536-7     Document Type: Article

References (65)

1. C.S. Higano, Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61(2), 32–38 (2003). doi:10.1016/S0090-4295(02)02397-X
2. L.G. Taylor, S.E. Canfield, X.L. Du, Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11), 2388–2399 (2009). doi:10.1002/cncr.24283
3. S.L. Greenspan, P. Coates, S.M. Sereika, J.B. Nelson, D.L. Trump, N.M. Resnick, Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J. Clin. Endocrinol. Metab. 90(12), 6410–6417 (2005). doi:10.1210/jc.2005-0183
4. S.M. Alibhai, L. Yun, A.M. Cheung, L. Paszat, Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3), 255–256 (2012). doi:10.1001/jama.2011.2022
5. National comprehensive cancer network: NCCN guidelines for prostate cancer (version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (2014). Accessed 14 Apr 2014
6. M. Grossmann, E.J. Hamilton, C. Gilfillan, D. Bolton, D.L. Joon, J.D. Zajac, Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med. J. Aust. 194(6), 301–306 (2011)
7. D.E. Bailey, M. Wallace, M.H. Mishel, Watching, waiting and uncertainty in prostate cancer. J. Clin. Nurs. 16(4), 734–741 (2007). doi:10.1111/j.1365-2702.2005.01545.x
8. J.L. Oliffe, B.J. Davison, T. Pickles, L. Mróz, The self-management of uncertainty among men undertaking active surveillance for low-risk prostate cancer. Qual. Health Res. 19(4), 432–443 (2009). doi:10.1177/1049732309332692
9. J.H. Littell, J. Corcoran, V.K. Pillai, Systematic reviews and meta-analysis. Pocket guides to social work research methods (Oxford University Press, Oxford, 2008)
10. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006–1012 (2009). doi:10.1016/j.jclinepi.2009.06.005
11. A.-C.M. Lassemillante, S.A. Doi, J.D. Hooper, J.B. Prins, O.R. Wright, Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45(3), 370–381 (2014). doi:10.1007/s12020-013-0083-z
12. D. Hoy, P. Brooks, A. Woolf, F. Blyth, L. March, C. Bain, P. Baker, E. Smith, R. Buchbinder, Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J. Clin. Epidemiol. 65(9), 934–939 (2012). doi:10.1016/j.jclinepi.2011.11.014
13. J.A. Kanis, L.J. Melton, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9(8), 1137–1141 (1994). doi:10.1002/jbmr.5650090802
14. E.M. Lewiecki, C.M. Gordon, S. Baim, M.B. Leonard, N.J. Bishop, M.-L. Bianchi, H.J. Kalkwarf, C.B. Langman, H. Plotkin, F. Rauch, B.S. Zemel, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, S. Silverman, International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone 43(6), 1115–1121 (2008). doi:10.1016/j.bone.2008.08.106
15. S.A. Doi, L. Thalib, A quality-effects model for meta-analysis. Epidemiology 19(1), 94–100 (2008)
16. S.A.R. Doi, J.J. Barendregt, E.L. Mozurkewich, Meta-analysis of heterogeneous clinical trials: an empirical example. Contemp. Clin. Trials 32(2), 288–298 (2011). doi:10.1016/j.cct.2010.12.006
17. H. Noma, Confidence intervals for a random-effects meta-analysis based on Bartlett-type corrections. Stat. Med. 30(28), 3304–3312 (2011). doi:10.1002/sim.4350
18. S.E. Brockwell, I.R. Gordon, A comparison of statistical methods for meta-analysis. Stat. Med. 20(6), 825–840 (2001). doi:10.1037/1082-989X.3.3.354
19. R.C. Overton, A comparison of fixed-effects and mixed (random-effects) models for meta-analysis tests of moderator variable effects. Psychol. Methods 3(3), 354 (1998). doi:10.1037/1082-989X.3.3.354
20. J.P. Hunter, A. Saratzis, A.J. Sutton, R.H. Boucher, R.D. Sayers, M.J. Bown, In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J. Clin. Epidemiol. 67(8), 897–903 (2014). doi:10.1016/j.jclinepi.2014.03.003
21. A.A. Onitilo, S.A.R. Doi, J.J. Barendregt, Meta-analysis I.I, in Methods of Clinical Epidemiology, Springer Series on Epidemiology and Public Health, ed. by S.A.R. Doi, G.M. Williams (Springer, Berlin Heidelberg, 2013), pp. 253–266
22. Epigear International: MetaXL. Version 2.0 (2014)
23. T. Yuasa, S. Maita, N. Tsuchiya, S. Takahashi, K. Hatake, I. Fukui, T. Habuchi, Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. J. Urol. 183(4), e335 (2010). doi:10.1016/j.urology.2009.10.075
24. J.H. Deng, L.P. Yang, L.S. Wang, D.F. Zhou, Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian J. Androl. 6(1), 75–77 (2004)
25. W. Wang, T. Yuasa, N. Tsuchiya, S. Maita, T. Kumazawa, T. Inoue, M. Saito, Z. Ma, T. Obara, H. Tsuruta, S. Satoh, T. Habuchi, Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr. Relat. Cancer 15(4), 943–952 (2008). doi:10.1677/erc-08-0116
26. A.H. Panju, H. Breunis, A.M. Cheung, M. Leach, N. Fleshner, P. Warde, S. Duff-Canning, M. Krahn, G. Naglie, I. Tannock, G. Tomlinson, S.M.H. Alibhai, Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int. 103(6), 753–757 (2009). doi:10.1111/j.1464-410X.2008.08156.x
27. J. Planas, J. Morote, A. Orsola, C. Salvador, E. Trilla, L. Cecchini, C.X. Raventos, J.P. Morin, The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 99(4), 812–815 (2007). doi:10.1111/j.1464-410X.2006.06695.x
28. E.Y. Yu, K.F. Kuo, R. Gulati, S. Chen, T.E. Gambol, S.P. Hall, P.Y. Jiang, P. Pitzel, C.S. Higano, Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J. Clin. Oncol. 30(15), 1864–1870 (2012). doi:10.1200/jco.2011.38.3745
29. J.T. Wei, M. Gross, C.A. Jaffe, K. Gravlin, M. Lahaie, G.J. Faerber, K.A. Cooney, Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54(4), 607–611 (1999). doi:10.1016/S0090-4295(99)00301-5
30. J. Morote, J.P. Morin, A. Orsola, J.M. Abascal, C. Salvador, E. Trilla, C.X. Raventos, L. Cecchini, G. Encabo, J. Reventos, Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69(3), 500–504 (2007). doi:10.1016/j.urology.2006.11.002
31. F.A. Conde, L. Sarna, R.K. Oka, D.L. Vredevoe, M.B. Rettig, W.J. Aronson, Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 64(2), 335–340 (2004). doi:10.1016/j.urology.2004.03.036
32. A. Berruti, L. Dogliotti, C. Terrone, S. Cerutti, G. Isaia, R. Tarabuzzi, G. Reimondo, M. Mari, P. Ardissone, S. De Luca, G. Fasolis, D. Fontana, S.R. Rossetti, A. Angeli, Gruppo Onco Urologico Piemontese, R.O.P., Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. Urol. 167(6), 2361–2367 (2002). doi:10.1016/S0022-5347(05)64985-3
33. S.A. Hussain, R. Weston, R.N. Stephenson, E. George, N.J. Parr, Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 92(7), 690–694 (2003). doi:10.1046/j.1464-410X.2003.04471.x
34. M.R. Smith, F.J. McGovern, M.A. Fallon, D. Schoenfeld, P.W. Kantoff, J.S. Finkelstein, Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91(12), 2238–2245 (2001). doi:10.1002/1097-0142(20010615)91
35. A. Cheung, D. Pattison, I. Bretherton, R. Hoermann, D. Lim Joon, E. Ho, T. Jenkins, E. Hamilton, K. Bate, I. Chan, Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology 1(4), 583–589 (2013). doi:10.1111/j.2047-2927.2013.00093
36. S. Alibhai, H. Mohamedali, H. Gulamhusein, A. Panju, H. Breunis, N. Timilshina, N. Fleshner, M. Krahn, G. Naglie, I. Tannock, Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporos. Int. 24(10), 2571–2579 (2013). doi:10.1007/s00198-013-2343-4
37. S. Ziaran, F.M. Goncalves, J.B. Sn, Complex metabolic and skeletal changes in men taking long-term androgen deprivation therapy. Clin. Genitourin. Cancer 11(1), 33–38 (2013). doi:10.1016/j.clgc.2012.08.005
38. A.C. Looker, E.S. Orwoll, C.C. Johnston, R.L. Lindsay, H.W. Wahner, W.L. Dunn, M.S. Calvo, T.B. Harris, S.P. Heyse, Prevalence of low femoral bone density in older US adults from NHANES III. J. Bone Miner. Res. 12(11), 1761–1768 (1997). doi:10.1359/jbmr.1997.12.11.1761
39. W. Demark-Wahnefried, D.J. Bowen, J.M. Jabson, E.D. Paskett, Scientific bias arising from sampling, selective recruitment, and attrition: the case for improved reporting. Cancer Epidemiol. Biomarkers Prev. 20(3), 415–418 (2011). doi:10.1158/1055-9965.epi-10-1169
40. T.V. Nguyen, J.R. Center, J.A. Eisman, Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J. Bone Miner. Res. 15(2), 322–331 (2000). doi:10.1359/jbmr.2000.15.2.322
41. R.C. Percival, G.H. Urwin, S. Harris, A.J. Yates, J.L. Williams, M. Beneton, J.A. Kanis, Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol. 13(1), 41–49 (1987)
42. G.H. Urwin, R.C. Percival, S. Harris, M.N. Beneton, J.L. Williams, J.A. Kanis, Generalised increase in bone resorption in carcinoma of the prostate. Br. J. Urol. 57(6), 721–723 (1985). doi:10.1111/j.1464-410X.1985.tb07040.x
43. P. Garnero, N. Buchs, J. Zekri, R. Rizzoli, R.E. Coleman, P.D. Delmas, Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82(4), 858–864 (2000). doi:10.1054/bjoc.1999.1012
44. T.A. Guise, G.R. Mundy, Cancer and Bone. Endocr. Rev. 19(1), 18–54 (1998). doi:10.1210/edrv.19.1.0323
45. T.H. Diamond, C.S. Higano, M.R. Smith, T.A. Guise, F.R. Singer, Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy. Cancer 100(5), 892–899 (2004). doi:10.1002/cncr.20056
46. C.J. Logothetis, S.H. Lin, Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5(1), 21–28 (2005). doi:10.1038/nrc1528
47. K.N. Weilbaecher, T.A. Guise, L.K. McCauley, Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11(6), 411–425 (2011). doi:10.1038/nrc3055
48. R. Murray, V. Grill, N. Crinis, P. Ho, J. Davison, P. Pitt, Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J. Clin. Endocrinol. Metab. 86(9), 4133–4138 (2001)
49. D.J. DiGirolamo, T.L. Clemens, S. Kousteni, The skeleton as an endocrine organ. Nat. Rev. Rheumatol. 8(11), 674–683 (2012). doi:10.1038/nrrheum.2012.157
50. M. Reuss-Borst, U. Hartmann, C. Scheede, J. Weiß, Prevalence of osteoporosis among cancer patients in Germany. Osteoporos. Int. 23(4), 1437–1444 (2012). doi:10.1007/s00198-011-1724-9
51. H.W. Daniell, J.C. Clark, S.E. Pereira, Z.A. Niazi, D.W. Ferguson, S.R. Dunn, M.L. Figueroa, P.T. Stratte, Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer 91(10), 1889–1895 (2001). doi:10.1002/1097-0142(20010515)91
52. T.O.M. Pickles, P. Graham, What happens to testosterone after prostate radiation monotherapy and does it matter? J. Urol. 167(6), 2448–2452 (2002). doi:10.1016/S0022-5347(05)65002-1
53. C. Fiorino, R. Valdagni, T. Rancati, G. Sanguineti, Dose–volume effects for normal tissues in external radiotherapy: Pelvis. Radiother. Oncol. 93(2), 153–167 (2009). doi:10.1016/j.radonc.2009.08.004
54. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, J.S. Goodwin, Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352(2), 154–164 (2005). doi:10.1056/NEJMoa041943
55. A.K. Morgans, M.R. Smith, A.J. O’Malley, N.L. Keating, Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer 119(4), 863–870 (2013). doi:10.1002/cncr.27830
56. A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin d from the institute of medicine: what clinicians need to know. J. Clin. Endocr. Metab. 96(1), 53–58 (2011). doi:10.1210/jc.2010-2704
57. M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, R.P. Heaney, M.H. Murad, C.M. Weaver, Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J. Clin. Endocr. Metab. 96(7), 1911–1930 (2011). doi:10.1210/jc.2011-0385
58. National Osteoporosis Foundation, Clinician’s guide to prevention and treatment of osteoporosis (National Osteoporosis Foundation, Washington, 2014)
59. Australian Cancer Network Management of Metastatic Prostate Cancer Working Party, Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer (Cancer Council Australia and Australian Cancer Network, Sydney, 2010)
60. National Collaborating Centre for Cancer, Prostate cancer: diagnosis and treatment. NICE Guidelines CG175 (National Institute for Health and Care Excellence, London, 2014)
61. H. Rhee, J.H. Gunter, P. Heathcote, K. Ho, P. Stricker, N.M. Corcoran, C.C. Nelson, Adverse effects of androgen deprivation therapy in prostate cancer and their management. BJU Int. (2014). doi:10.1111/bju.12964
62. ® and its applications to clinical practice. Bone 44(5), 734–743 (2009). doi:10.1016/j.bone.2009.01.373
63. J. Kanis, O. Johnell, A. Odén, H. Johansson, E. McCloskey, FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19(4), 385–397 (2008). doi:10.1007/s00198-007-0543-5
64. P.J. Saylor, D.S. Kaufman, M.D. Michaelson, R.J. Lee, M.R. Smith, Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J. Urol. 183(6), 2200–2205 (2010). doi:10.1016/j.juro.2010.02.022
65. ®. Osteoporos. Int. 21(4), 647–653 (2010). doi:10.1007/s00198-009-0984-0